Actively Recruiting
A Study to Examine Anktiva for the Treatment of COVID-19.
Led by ImmunityBio, Inc. · Updated on 2026-05-13
40
Participants Needed
1
Research Sites
42 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
CONDITIONS
Official Title
A Study to Examine Anktiva for the Treatment of COVID-19.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to less than 70 years
- History of at least one confirmed SARS-CoV-2 infection by NAAT or antigen test
- Clinical evidence of Long COVID confirmed by investigator
- At least 2 new or worsened symptoms since SARS-CoV-2 infection or at least 1 severe symptom, lasting at least 60 days
- Symptoms reported as bothersome and impacting quality of life or daily functioning
- At least 90 days elapsed since most recent suspected or confirmed SARS-CoV-2 infection
- Not currently hospitalized
- Body mass index (BMI) between 18 and 50 kg/m2 inclusive
- Otherwise stable health as assessed by investigator within 28 days prior to screening
- For males with partners who can become pregnant, agreement to use effective contraception during study and 7 months after last dose
- For females sexually active with males, not pregnant or breastfeeding and agreement to contraception and pregnancy testing as required
- Willingness and ability to comply with study protocol and attend all visits
- Written informed consent obtained
You will not qualify if you...
- Received SARS-CoV-2 antiviral or monoclonal antibody within 30 days prior to planned treatment or plan to receive before study exit
- Plans to receive any SARS-CoV-2 vaccine or booster within 14 days prior to planned treatment or before study exit
- History of autoimmune diseases including celiac disease, rheumatoid arthritis, psoriasis, inflammatory bowel diseases
- Active cardiovascular disease such as recent myocardial infarction, recent coronary artery bypass, heart failure with reduced ejection fraction, or pulmonary arterial hypertension
- Stroke within 3 months prior to planned treatment
- Active infection other than SARS-CoV-2 requiring treatment within 14 days prior to treatment
- Major surgery within 3 months prior to treatment or planned major surgery during first 75 days after treatment
- Unplanned hospitalization over 24 hours within 28 days prior to screening
- Active or prior Hepatitis B infection
- Active Hepatitis C infection; cured Hepatitis C allowed
- Laboratory abnormalities including low ANC, low platelet count, low hemoglobin, elevated liver enzymes, or reduced kidney function
- Known or suspected HIV infection
- End stage kidney disease requiring dialysis
- Diabetes requiring systemic medication or insulin
- Severe liver impairment (Child-Pugh Class C)
- Moderate or severe immunocompromise including recent cancer treatment, organ transplant, immunodeficiency syndromes, high-dose corticosteroids
- Prior diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome not related to COVID-19
- Prior diagnosis of dysautonomia not related to COVID-19
- Allergy to components of study drug or history of severe allergic reactions
- Participation in clinical trial with investigational product within 28 days prior to treatment except certain imaging studies
- Current alcohol or illicit drug use interfering with participation
- Any condition that investigator believes would compromise safety or data quality
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chan Soon-Schiong Institute for Medicine (CSSIFM)
El Segundo, California, United States, 90245
Actively Recruiting
Research Team
K
Kayleigh Russell
CONTACT
J
Jayson Garmizo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here